DEVELOPMENT AND EVALUATION OF TRANSDERMAL FILM CONTAINING SOLID LIPID NANOPARTICLES OF RIVASTIGMINE TARTRATE
Objective: The objective of present investigation was to develop rivastigmine tartrate transdermal film employing factorial design.
Methods: The formulations were designed by Design-Expert software-version10. A series of films were prepared by solvent casting method using polymers, plasticizer, permeation enhancer and other solvents. Transdermal films were evaluated for flatness, drug content, tensile strength, in vitro drug release and ex vivo skin permeation study.
Results: The flatness was found 100% (percentage) for all film formulations. The drug content of transdermal film was found in the range of 96.51Â±0.2 to 98.81Â±0.3%. The tensile strength of transdermal film was found in the range of 6.28Â±0.06 to 11.56Â±0.03 N/mm2 (newton/millimeter2) and in vitro drug release at 24th h (hour) was found in the range of 86.24Â±0.25 to 96.1Â±0.48%% for various formulations and ex vivo skin permeation study results at 24th h was found in the range of 85.83Â±0.74 to 97.36Â±0.93%.
Conclusion: These results support the feasibility of developing transdermal film of rivastigmine tartrate for human applications. Thus, transdermal delivery of rivastigmine tartrate film is a safe, painless and cost effective drug delivery system for Alzheimerâ€™s patients.
2. Frances A. American psychiatric association. Diagnostic and statistical manual of mental disorders: DSM-IV: Prepared by the Task Force on DSM-IV (4th ed.). Washington, DC: American Psychiatric Association; 1994.
3. Gaugler JE, Duval S, Anderson KA, Kane RL. Predicting nursing home admission in the U. S: A meta-analysis. BMC Geriatrics 2007;7:13.
4. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discovery 2004;3:115-24.
5. Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Delivery 2005;2:23-33.
6. Cramer MP, Saks SR. Translating safety, efficacy and compliance into economic value for controlled-release dosage forms. Pharmacoeconomics 1994;5:482-504.
7. Michaels AS, Chandrasekaran SK, Shaw JE. Drug permeation through human skinâ€“theory and in vitro experimental measurements. Aiche J 1975;21:985-96.
8. Basu B, Garala K, Bhalodia R, Joshi B, Mehta K. Solid lipid nanoparticles: a promising tool for drug delivery system. J Pharm Res 2010;3:84-92.
9. Viveksarathi K, Kannan K. Compatibility studies of rasagiline mesylate with selected excipients for an effective solid lipid nanoparticles formulation. Int J Pharm Pharm Sci 2015;7:73-80.
10. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77.
11. Kreuter J. Colloidal drug delivery systems. Vol. 66. CRC Press; 1994.
12. Bhattacharya R, Mukherjee P. Biological properties of. Adv. Drug Delivery Rev 2008;60:1289-306.
13. Manchester M, Singh P. Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Delivery Rev 2006;58:1505-22.
14. Rakesh KS, Navneet S, Sudha R, Shivkumar HG. Solid lipid nanoparticles as a carrier of metformin for transdermal delivery. Int J Drug Delivery 2013;5:137-45.
15. Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci 2001;13:123-33.
16. Lingheswar S, Nibedita D, Arul PF, Thiyagarajan D. Transdermal films of chitosan nanoparticles for insulin delivery. Int J Pharm Pharm Sci 2015;7:84-8.
17. Garala K, Shinde A. Formulation and in vitro characterization of monolithic matrix transdermal systems using HPML/eudragit S 100 polymer blends. Int J Pharm Pharm Sci 2009;1:108-17.
18. Gupta R, Mukherjee B. Development and in vitro evaluation of diltiazem hydrochloride transdermal films based on povidone-ethylcellulose matrices. Drug Dev Ind Pharm 2003;29:1-7.
19. Arora P, Mukherjee B. Design, development, physicochemical, and in vitro and in vivo evaluation of transdermal films containing diclofenac diethyl ammonium salt. J Pharm Sci 2002;91:2076-89.
20. Agrawal SS, Munjal P. Permeation studies of atenolol and metaprolol tartrate from three different polymer matrices for transdermal delivery. Indian J Pharm Sci 2007;69:535-9.
21. Aquil M, Sultana Y, Ali A. Matrix type transdermal drug delivery systems of metoprolol tartrate: in vitro characterization. Acta Pharm 2003;53:119-25.
22. Keleb E, Sharma RK, Mosa EB, Aljahwi AZ. Transdermal drug delivery system-design and evaluation. Int J Adv Pharm Sci 2010;1:201-11.
23. Faseen M, Laxmi SB, Vijaya KB, Sateesh KV. Formulation and evaluation of transdermal films of Ondansetron hydrochloride. MOJ Bioequiv Availab 2017;3:1-7.
24. Vandana M, Rachna A, Anupam KP. Preparation and evaluation of Captopril transdermal films. Bull Pharm Res 2011;1:47-52.
25. Garala KC, Shinde AJ, Shah PH. Formulation and in vitro characterization of monolithic matrix transdermal systems using HPMC/Eudragit S 100 polymer blends. Int J Pharm Pharm Sci 2009;1:108-20.
26. Nabajyoti G, Ankur G, Bijoy N. Free radical scavenging activities of Garcinia xanthochymus Hook F, Garcinia lanceaefoliaroxb. Using various in vitro assay models. Asian J Pharm Clin Res 2015;8:138-41.
27. Hua Y, Jianga X, Dinga Y, Zhanga L, Yanga C, Zhang J. Preparation and drug release behaviours of nimodipine-loaded poly (caprolactone)-poly (ethyleneoxide)-polylactideamphiphilic copolymer nanoparticles. Biomaterials 2003;24:2395â€“404.
28. Ganesh Chandra S, Keishiro T. In vitro permeation of gold nanoparticles through rat skin and rat intestine: Effect of particle size. Colloids Surf B 2008;65:1-10.
29. Sahar MF, Shadeed G, EL-Sayed AK, Gehad AA, Mamdouh MG, Sohier AE. Formulation and evaluation of etodolac lecithin organogel transdermal delivery systems. Int J Pharm Pharm Sci 2015;7:325-34.
30. Swetha V, Devareddy S. Formulation and evaluation of a matrix-type transdermal patch containing rivastigmine tartrate. Int J Pharm Sci Res 2013;4:10-6.
31. Pramod S, Suvarna P, Nikhil B. Formulation and evaluation of solid lipid nanoparticle based transdermal drug delivery system for Alzheimerâ€™s disease. Res J Pharm Dosage Forms Tech 2016;8:73-80.